{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:41:19Z","timestamp":1785894079968,"version":"3.56.0"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100007827","name":"American College of Gastroenterology","doi-asserted-by":"publisher","award":["K76AG083286"],"award-info":[{"award-number":["K76AG083286"]}],"id":[{"id":"10.13039\/100007827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Lay Summary<\/jats:title>\n                  <jats:p>In this study, we assessed the safety and effectiveness of risankizumab dose escalation in patients with incomplete response to standard dosing. We found that dose escalation was well tolerated and associated with lower rates of corticosteroid usage and few adverse events.<\/jats:p>","DOI":"10.1093\/ibd\/izaf130","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T07:49:37Z","timestamp":1748591377000},"page":"3225-3227","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Risankizumab Dose Escalation Among Patients With Inflammatory Bowel Disease"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7386-8754","authenticated-orcid":false,"given":"William","family":"Schreiber-Stainthorp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-5856","authenticated-orcid":false,"given":"Adam S","family":"Faye","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-7790","authenticated-orcid":false,"given":"Jordan E","family":"Axelrad","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, NYU Grossman School of Medicine , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"10340","key":"2025112116471154800_CIT0001","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet."},{"issue":"10340","key":"2025112116471154800_CIT0002","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet."},{"issue":"7","key":"2025112116471154800_CIT0003","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"11","key":"2025112116471154800_CIT0004","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for ulcerative colitis: two randomized clinical trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA."},{"issue":"12","key":"2025112116471154800_CIT0005","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1007\/s10620-022-07488-7","article-title":"Weight and BMI patterns in a biologicals-treated IBD cohort","volume":"67","author":"Kaazan","year":"2022","journal-title":"Dig Dis Sci."},{"issue":"10S","key":"2025112116471154800_CIT0006","doi-asserted-by":"publisher","first-page":"S1076","DOI":"10.14309\/01.ajg.0001035328.04327.b3","article-title":"S1490 dose intensification of risankizumab for Crohn\u2019s disease: access and outcomes","volume":"119","author":"Dalal","year":"2024","journal-title":"Am J Gastroenterol."},{"issue":"4","key":"2025112116471154800_CIT0007","doi-asserted-by":"publisher","first-page":"853","DOI":"10.3390\/jcm10040853","article-title":"Predictors and early markers of response to biological therapies in inflammatory bowel diseases","volume":"10","author":"Privitera","year":"2021","journal-title":"J Clin Med."},{"issue":"12","key":"2025112116471154800_CIT0008","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.cgh.2024.04.016","article-title":"Long-term outcome of risankizumab in Crohn\u2019s disease: a real-world GETAID study","volume":"22","author":"Fumery","year":"2024","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf130\/63570971\/izaf130.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/3225\/63570971\/izaf130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/3225\/63570971\/izaf130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:47:20Z","timestamp":1763761640000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/11\/3225\/8172980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":8,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf130","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,24]]}}}